Sandoz stock: Two medicine launches broaden growth options

Published on 11/14/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock was in focus after two medicine launches during the week. Owozy entered Brazil, while Ranluspec expanded the European ophthalmology portfolio.

Sandoz expands its medicine portfolio

Sandoz launched the Owozy semaglutide treatment in Brazil on November 9, 2026.
The company launched the Ranluspec ranibizumab biosimilar across Europe, excluding Germany, on November 12, 2026.
The two launches broaden Sandoz's presence in diabetes care and ophthalmology.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz added two commercial products to its portfolio during the week of November 9 to 13, 2026. On November 9, the company launched Owozy, a semaglutide treatment for adults with insufficiently controlled type 2 diabetes, in Brazil, according to Sandoz's release.

The Brazil launch is Sandoz's first semaglutide launch. Owozy was developed by Adalvo, received approval from Brazil's health regulator in July 2026 and is being commercialised locally with Biolab & Co. The company said the product supports its ambition to build a position in the generic GLP-1 market.

Ranluspec broadens European eye care

On November 12, 2026, Sandoz launched Ranluspec, a biosimilar version of ranibizumab, across Europe excluding Germany. The launch was announced by development and manufacturing partner Lupin in a press release.

Ranluspec is intended for several retinal conditions, including wet age-related macular degeneration, diabetic macular oedema and retinal vein occlusion-related macular oedema. Lupin said the product is available in vial and pre-filled syringe presentations.

Saturday quote and investor context

Sandoz stock traded at 91.87 euros on Lang & Schwarz at 12:24 CET on Saturday, November 14. The two launches add commercial options in diabetes care and ophthalmology, while their financial contribution will depend on market uptake, pricing and local reimbursement.